Evidence map›Paper›PMID 39954291›Full record

ArticleMolecular pharmaceutics2025

Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications.

Rebecca Rizzo, Martina Capozza, Laura Conti, Lidia Avalle, Valeria Poli, Enzo Terreno

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Erasable FAP Targeted Spray-On Probe for Fluorescence-Guided Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca RizzoDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44/bis, Turin 10126, Italy.ORCID 0000-0002-8810-110X
Martina CapozzaDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44/bis, Turin 10126, Italy.ORCID 0000-0001-9125-8004
Laura ContiDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44/bis, Turin 10126, Italy.
Lidia AvalleDISIT, University of Eastern Piedmont, Viale Teresa Michel 11, Alessandria 15121, Italy.
Valeria PoliDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin 10126, Italy.
Enzo TerrenoDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44/bis, Turin 10126, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is a pan-cancer target that is useful for imaging, ideally all epithelial cancers. This work aimed to develop, characterize, and validate two novel FAP-targeted probes for optical imaging, both in

Indexed as

Breast NeoplasmsCarbocyaninesMembrane ProteinsOptical ImagingSerine EndopeptidasesAnimalsCell Line, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaFluorescent DyesHumansMiceMice, NudeSpectroscopy, Near-InfraredTissue DistributionCarbocyaninesEndopeptidasesFibroblast Activation Protein AlphaFluorescent DyesMembrane ProteinsSerine Endopeptidasesbreast cancerFAPheptamethine cyaninesnear-infrared fluorescence imagingoptical imaging

Identifiers

PMID39954291
PMCPMC11881144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.